Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface

Understanding the mechanism of action of modulator compounds for the cystic fibrosis transmembrane conductance regulator (CFTR) is key for the optimization of therapeutics as well as obtaining insights into the molecular mechanisms of CFTR function. We demonstrate the direct binding of VX-809 to the first nucleotide-binding domain (NBD1) of human CFTR. Disruption of the interaction between C-terminal helices and the NBD1 core upon VX-809 binding is observed from chemical shift changes in the NMR spectra of residues in the helices and on the surface of β-strands S3, S9, and S10. Binding to VX-809 leads to a significant negative shift in NBD1 thermal melting temperature (Tm), pointing to direct VX-809 interaction shifting the NBD1 conformational equilibrium. An inter-residue correlation analysis of the chemical shift changes provides evidence of allosteric coupling between the direct binding site and the NBD1:CL4 interface, thus enabling effects on the interface in the absence of direct binding in that location. These NMR binding data and the negative Tm shifts are very similar to those previously reported by us for binding of the dual corrector-potentiator CFFT-001 to NBD1 (Hudson et al., 2012), suggesting that the two compounds may share some aspects of their mechanisms of action. Although previous studies have shown an important role for VX-809 in modulating the conformation of the first membrane spanning domain (Aleksandrov et al., 2012; Ren et al., 2013), this additional mode of VX-809 binding provides insight into conformational dynamics and allostery within CFTR.

[1]  G. Lukács,et al.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.

[2]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[3]  Zhengrong Yang,et al.  Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis , 2010, Protein science : a publication of the Protein Society.

[4]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[5]  Hong Yu Ren,et al.  VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1 , 2013, Molecular biology of the cell.

[6]  Sylvain Brohée.  Using the NeAT toolbox to compare networks to networks, clusters to clusters, and network to clusters. , 2012, Methods in molecular biology.

[7]  Hanoch Senderowitz,et al.  Conformational Changes Relevant to Channel Activity and Folding within the first Nucleotide Binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator* , 2012, The Journal of Biological Chemistry.

[8]  Chandrima Sinha,et al.  Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry , 2015, Chembiochem : a European journal of chemical biology.

[9]  Adrian W. R. Serohijos,et al.  Phenylalanine-508 mediates a cytoplasmic–membrane domain contact in the CFTR 3D structure crucial to assembly and channel function , 2008, Proceedings of the National Academy of Sciences.

[10]  Angus C Nairn,et al.  In vivo phosphorylation of CFTR promotes formation of a nucleotide‐binding domain heterodimer , 2006, The EMBO journal.

[11]  R. Crystal,et al.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. , 1991, Nature.

[12]  Philip J. Thomas,et al.  Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.

[13]  H. Senderowitz,et al.  The Cystic Fibrosis-causing Mutation ΔF508 Affects Multiple Steps in Cystic Fibrosis Transmembrane Conductance Regulator Biogenesis* , 2010, The Journal of Biological Chemistry.

[14]  Frank Harary,et al.  Graph Theory , 2016 .

[15]  K. Du,et al.  Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.

[16]  J. Riordan,et al.  Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  D. Clarke,et al.  Corrector VX-809 stabilizes the first transmembrane domain of CFTR. , 2013, Biochemical pharmacology.

[18]  D. Sheppard,et al.  Gating of the CFTR Cl− channel by ATP‐driven nucleotide‐binding domain dimerisation , 2009, The Journal of physiology.

[19]  Pradeep Kota,et al.  Rational coupled dynamics network manipulation rescues disease-relevant mutant cystic fibrosis transmembrane conductance regulator , 2014, Chemical science.

[20]  A. Mittermaier,et al.  Deletion of Phenylalanine 508 in the First Nucleotide-binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization*♦ , 2015, The Journal of Biological Chemistry.

[21]  Zhengrong Yang,et al.  Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide‐binding domain 1 , 2010, Protein science : a publication of the Protein Society.

[22]  M. Newman,et al.  Random graphs with arbitrary degree distributions and their applications. , 2000, Physical review. E, Statistical, nonlinear, and soft matter physics.

[23]  J. Forman-Kay,et al.  Allosteric Coupling between the Intracellular Coupling Helix 4 and Regulatory Sites of the First Nucleotide-binding Domain of CFTR , 2013, PloS one.

[24]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[25]  Isabelle Callebaut,et al.  Molecular models of the open and closed states of the whole human CFTR protein , 2009, Cellular and Molecular Life Sciences.

[26]  Bruce A. Johnson,et al.  NMR View: A computer program for the visualization and analysis of NMR data , 1994, Journal of biomolecular NMR.

[27]  Pradeep Kota,et al.  Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. , 2012, Journal of molecular biology.

[28]  Slavica Jonic,et al.  Full-open and closed CFTR channels, with lateral tunnels from the cytoplasm and an alternative position of the F508 region, as revealed by molecular dynamics , 2014, Cellular and Molecular Life Sciences.

[29]  R. Fisher,et al.  Statistical Methods for Research Workers , 1930, Nature.

[30]  Jue Chen,et al.  Atomic Structure of the Cystic Fibrosis Transmembrane Conductance Regulator , 2016, Cell.

[31]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[32]  Giuseppe Melacini,et al.  Mapping allostery through the covariance analysis of NMR chemical shifts , 2011, Proceedings of the National Academy of Sciences.

[33]  Julie D. Forman-Kay,et al.  Binding screen for cftr correctors finds new chemical matter and yields insights into cf therapeutic strategy , 2015 .

[34]  J. M. Sauder,et al.  Structure of nucleotide‐binding domain 1 of the cystic fibrosis transmembrane conductance regulator , 2004, The EMBO journal.

[35]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[36]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[37]  Susan S. Taylor,et al.  D‐AKAP2:PKA RII:PDZK1 ternary complex structure: Insights from the nucleation of a polyvalent scaffold , 2015, Protein science : a publication of the Protein Society.

[38]  John F Hunt,et al.  Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. , 2010, Protein engineering, design & selection : PEDS.

[39]  S. McColley,et al.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.

[40]  A. Evagelidis,et al.  Phosphorylation of CFTR by PKA promotes binding of the regulatory domain , 2005, The EMBO journal.

[41]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[42]  M. Welsh,et al.  Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channel by Its R Domain* , 2001, The Journal of Biological Chemistry.

[43]  D. Clarke,et al.  The V510D Suppressor Mutation Stabilizes ΔF508-CFTR at the Cell Surface† , 2010, Biochemistry.

[44]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[45]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[46]  D. Gadsby,et al.  Molecular Structure of the Human CFTR Ion Channel , 2017, Cell.

[47]  Zhengrong Yang,et al.  Restoration of NBD1 thermal stability is necessary and sufficient to correct ∆F508 CFTR folding and assembly. , 2015, Journal of molecular biology.

[48]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .